BRPI1009573A2 - método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente. - Google Patents

método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.

Info

Publication number
BRPI1009573A2
BRPI1009573A2 BRPI1009573A BRPI1009573A BRPI1009573A2 BR PI1009573 A2 BRPI1009573 A2 BR PI1009573A2 BR PI1009573 A BRPI1009573 A BR PI1009573A BR PI1009573 A BRPI1009573 A BR PI1009573A BR PI1009573 A2 BRPI1009573 A2 BR PI1009573A2
Authority
BR
Brazil
Prior art keywords
autoantibody
assessing
kit
patient
subject
Prior art date
Application number
BRPI1009573A
Other languages
English (en)
Inventor
Marotta Anthony
Original Assignee
Augurex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augurex Life Sciences Corp filed Critical Augurex Life Sciences Corp
Publication of BRPI1009573A2 publication Critical patent/BRPI1009573A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1009573A 2009-03-11 2010-03-11 método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente. BRPI1009573A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15938609P 2009-03-11 2009-03-11
PCT/CA2010/000368 WO2010102412A1 (en) 2009-03-11 2010-03-11 Compositions and methods for characterizing arthritic conditions

Publications (1)

Publication Number Publication Date
BRPI1009573A2 true BRPI1009573A2 (pt) 2017-07-18

Family

ID=42727761

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009573A BRPI1009573A2 (pt) 2009-03-11 2010-03-11 método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.

Country Status (16)

Country Link
US (2) US11054419B2 (pt)
EP (1) EP2406633B1 (pt)
JP (1) JP5792637B2 (pt)
KR (1) KR101894597B1 (pt)
CN (1) CN102414563B (pt)
AU (1) AU2010223776B2 (pt)
BR (1) BRPI1009573A2 (pt)
CA (1) CA2754741C (pt)
DK (1) DK2406633T3 (pt)
ES (1) ES2714216T3 (pt)
HU (1) HUE043684T2 (pt)
IL (1) IL215056A (pt)
PL (1) PL2406633T3 (pt)
PT (1) PT2406633T (pt)
TR (1) TR201902845T4 (pt)
WO (1) WO2010102412A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2768851T (pt) * 2011-10-21 2017-09-08 Augurex Life Sciences Corp Antigénios derivados de 14-3-3 citrulinada e utilizações dos mesmos no diagnóstico de artrite reumatoide
CN114354919A (zh) * 2018-01-05 2022-04-15 科美诊断技术股份有限公司 检测14-3-3 eta蛋白的均相免疫检测试剂盒及其应用
WO2019217916A1 (en) * 2018-05-10 2019-11-14 The Methodist Hospital Methods for prognosis and management of disease
CN110531073B (zh) * 2018-05-23 2024-03-15 科美诊断技术股份有限公司 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法
CN110579597A (zh) * 2018-05-23 2019-12-17 科美诊断技术股份有限公司 检测14-3-3 eta蛋白的非均相化学发光免疫检测试剂盒及其应用
CN110579600B (zh) * 2018-05-23 2023-12-26 科美诊断技术股份有限公司 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法
CN110579601B (zh) * 2018-05-24 2023-12-26 科美诊断技术股份有限公司 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法
CN110726843A (zh) * 2018-07-16 2020-01-24 科美诊断技术股份有限公司 检测14-3-3eta蛋白的化学发光免疫检测试剂盒及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US5948765A (en) 1996-03-15 1999-09-07 Washington University Inhibition of intracellular signal transduction by 14-3-3-binding peptides
US5998149A (en) 1996-04-05 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Method of detecting transmissible spongiform encephalopathies
US5814507A (en) 1996-05-24 1998-09-29 Genentech, Inc. κ/μ-like protein tyrosine phosphatase, PTP λ
WO1998026293A1 (en) 1996-12-12 1998-06-18 Neuromark Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms
US20020173454A1 (en) * 2000-01-31 2002-11-21 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7056677B2 (en) 2000-03-17 2006-06-06 Gemini Science, Inc. Soluble mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them
KR100380147B1 (ko) 2001-01-18 2003-04-11 주식회사 엘지생명과학 류마티스성 자가면역 항체의 검출방법 및 검출키트
WO2002067968A2 (en) 2001-02-21 2002-09-06 Emory University 14-3-3 binding molecules as sensitizers for anticancer therapies
DE60233301D1 (de) * 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
DE10131912A1 (de) 2001-06-06 2002-12-19 Werner E G Mueller Verwendung von 14-3-3 Proteinen und Verfahren zu deren Bestimmung
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7172905B2 (en) * 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
GB0208331D0 (en) 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
US7101962B2 (en) 2003-05-15 2006-09-05 Bristol-Myers Squibb Company Antibodies of the P2Y10 receptor useful in altering T lymphocyte function
AU2004249814A1 (en) 2003-06-25 2004-12-29 Queen's University At Kingston Methods for diagnosing, monitoring, staging and treating heart failure
AU2004294933B2 (en) 2003-11-21 2011-11-17 Johns Hopkins University Biomolecule partition motifs and uses thereof
TWI281473B (en) 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
US7396654B2 (en) 2004-04-15 2008-07-08 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for traumatic brain injury
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
EP2021792B1 (en) * 2006-05-09 2013-02-27 The University Of British Columbia Dissolved protein arthritis markers
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090093005A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US7919262B2 (en) 2007-11-07 2011-04-05 The Uab Research Foundation 14-3-3 proteins for diagnosis of Parkinson's disease
KR20180102215A (ko) * 2007-11-27 2018-09-14 더 유니버시티 오브 브리티쉬 콜롬비아 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
CN102171569A (zh) * 2008-05-09 2011-08-31 杜克大学 检测和治疗癌症的自身抗体
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA2809282C (en) 2010-09-27 2017-09-12 Somalogic, Inc. Mesothelioma biomarkers and uses thereof

Also Published As

Publication number Publication date
AU2010223776A1 (en) 2011-10-20
JP2012519860A (ja) 2012-08-30
KR101894597B1 (ko) 2018-10-04
IL215056A (en) 2015-10-29
CN102414563B (zh) 2014-12-03
EP2406633B1 (en) 2019-01-16
HUE043684T2 (hu) 2019-09-30
EP2406633A4 (en) 2012-08-29
US11054419B2 (en) 2021-07-06
IL215056A0 (en) 2011-11-30
CA2754741A1 (en) 2010-09-16
US20210333276A1 (en) 2021-10-28
US20120058498A1 (en) 2012-03-08
PL2406633T3 (pl) 2019-07-31
JP5792637B2 (ja) 2015-10-14
AU2010223776B2 (en) 2016-08-25
WO2010102412A1 (en) 2010-09-16
PT2406633T (pt) 2019-03-14
EP2406633A1 (en) 2012-01-18
CN102414563A (zh) 2012-04-11
DK2406633T3 (en) 2019-04-01
TR201902845T4 (tr) 2019-03-21
KR20120004990A (ko) 2012-01-13
CA2754741C (en) 2019-02-12
ES2714216T3 (es) 2019-05-27

Similar Documents

Publication Publication Date Title
EP2473637A4 (en) PROCEDURE FOR TREATMENT, DIAGNOSIS AND MONITORING RHEUMATOID ARTHRITIS
BRPI1009573A2 (pt) método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.
BRPI0917910A2 (pt) método para detectar amostra de aspereza e aparelho para o método
IL233098A0 (en) Ratio based biomarkers and methods of use thereof
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
IL242040A (en) Systems and methods for detecting defects on a wafer
BRPI0906858A2 (pt) Métodos para detecção de assinaturas de doença ou condições em fluidos corporais
BRPI0817114A2 (pt) Detector de desconexão de acesso e método para detectar uma desconexão de acesso
BR112012033664A2 (pt) métodos para detecção da presença ou ausência de micro-organismos em uma amostra e dispositivo para detecção de micro-organismos
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
EP2164086A4 (en) INDICATOR, DETECTOR AND DETECTION METHOD
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
BR112012018103A2 (pt) método para detectar a presença de uma amostra de testemunhagem dentro de uma ferramenta de testemunhagem, método para perfurar dentro de um poço com uma ferramenta de testemunhagem, e método para detectar a presença de uma amostra de testemunhagem dentro de uma ferramenta de testemunhagem
BRPI1008199A2 (pt) sistema de detecção capacitiva para detectar um objeto, método de deteção capacitiva para detectar um objeto e programa de computador para detectar um objeto
BRPI0820721A2 (pt) Reagentes e métodos para detectar analitos
BRPI1014353A2 (pt) "método e dispositivo para detectar uma situação de aprisionamento"
JP2010048806A5 (ja) 流体内検体濃度検知システム
BRPI1015212A2 (pt) dispositivo e método para a detecção e para a análise quantitativa de analitos, especialmente micotoxinas
EP3076152A4 (en) Corrosion reagent for detecting steel macrostructure and defect, and detection method
BR112012000694A2 (pt) dispositivo de detecção de contato para detectar um contato físico entre o dispositivo de detecção de contato e um objeto, método de operação de um dispositivo de detecção de contato para detecção"
EP2413129A4 (en) LIFE DETECTION DEVICE
CL2011002260A1 (es) Metodo o sistema para el seguimiento del tratamiento de un individuo que comprende determinar si una muestra de dicho individuo comprende un biomarcador.
PT2646565T (pt) Método de deteção e quantificação de microrganismos
BR112012004367A2 (pt) método de detecção de adulteração.

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements